Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update
by Sarita Garza · The Markets DailyNovozymes A/S (OTCMKTS:NVZMY – Get Free Report) was the recipient of a large decrease in short interest in the month of August. As of August 14th, there was short interest totaling 1,871 shares, a decrease of 48.1% from the July 30th total of 3,603 shares. Based on an average daily trading volume, of 38,102 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the company’s stock are short sold.
Wall Street Analyst Weigh In
Several equities analysts have commented on NVZMY shares. Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Kepler Capital Markets raised Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Novozymes A/S currently has an average rating of “Buy”.
View Our Latest Stock Analysis on Novozymes A/S
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Novozymes A/S stock. Elefante Mark B grew its position in Novozymes A/S (OTCMKTS:NVZMY – Free Report) by 73.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.
Novozymes A/S Stock Down 0.3%
NVZMY stock traded down $0.21 during mid-day trading on Monday, reaching $71.68. The company had a trading volume of 30,536 shares, compared to its average volume of 68,483. The firm has a fifty day simple moving average of $65.12 and a 200 day simple moving average of $61.02. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a current ratio of 1.67. The company has a market capitalization of $29.71 billion, a price-to-earnings ratio of 45.37, a price-to-earnings-growth ratio of 3.16 and a beta of 0.92. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.27.
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last announced its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.16). Novozymes A/S had a return on equity of 6.60% and a net margin of 14.70%.The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.27 billion. Analysts forecast that Novozymes A/S will post 2.47 earnings per share for the current fiscal year.
Novozymes A/S Company Profile
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).